Printer Friendly

Cancer Research UK's commercial unit signs contract with Leukaemia & Lymphoma Research.

M2 EQUITYBITES-October 29, 2014-Cancer Research UK's commercial unit signs contract with Leukaemia & Lymphoma Research

(C)2014 M2 COMMUNICATIONS http://www.m2.com

Cancer Research UK's commercial unit has signed a contract with Leukaemia & Lymphoma Research, it was reported yesterday. The agreement has been signed to co-fund the early-phase human clinical trials of experimental blood cancer drugs.

According to the contract, Leukaemia & Lymphoma Research will provide access to new therapies currently being researched by its scientists and provide financial support for Cancer Research UK to develop these therapies through preclinical and early-phase clinical development.

Cancer Research UK's Centre for Drug Development will manage these clinical trials at various hospitals throughout the United Kingdom. As part of the five-year deal, around five clinical trials will be financed using funds collected from successfully marketed drugs that are being shared by both parties.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2014 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Geographic Code:4EUUK
Date:Oct 29, 2014
Words:150
Previous Article:Associated declares higher dividend and USD120m stock buy back programme.
Next Article:TUI Travel shareholders greenlight merger with German parent.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters